Aim There is wide disparity in the care of patients with multivisceral involvement of rectal cancer. The results are presented of treatment of advanced and recurrent colorectal cancer from a centre where a dedicated multidisciplinary team (MDT) is central to the management.
Introduction
Colorectal cancer (CRC) accounts for 13% of all cancers and is the third most frequent cancer in the 28 countries of the European Union after breast and prostate cancer. It is the second most frequent cause of death after lung cancer [1] . Although the incidence of colon cancer is declining with improved surveillance and prevention of polyp progression, the incidence of rectal cancer in younger patients is increasing by 2.6% a year in the USA [2] . In the UK, 33% of the 14 000 newly diagnosed rectal cancers per year will be locally advanced on presentation [3, 4] . If left untreated the prognosis is poor, with a median survival of less than 1 year and a 5-year survival of less than 5% [5] [6] [7] .
Total mesorectal excision (TME) combined with neoadjuvant radiotherapy has led to margin negative rates approaching 90% and local recurrence rates of between 4% and 10% [3, 8, 9] . Although radiotherapy and chemotherapy can downstage cancers so that conventional TME will allow complete surgical resection, approximately 6% of rectal cancers will still be found to have invaded adjacent structures (stage-T4) [3, 9] . There is a lot of literature describing the natural history of locally advanced primary or recurrent colorectal cancer but there is no established management protocol for these patients regarding the timing of surgery. Despite the important role of chemo/radiotherapy in palliation and symptom control of locally extensive rectal cancer, surgical resection involving a multivisceral or exenterative approach, is the only potentially curative option [10, 11] . Previous irradiation, distorted mesorectal planes and aggressive tumour biology can, however, lead to a higher risk of R1 or R2 resection, defined as residual microscopic or macroscopic tumour after surgery, a high rate of postoperative adverse events, varying survival rates and increased difficulty of future salvage surgery [12] [13] [14] .
Currently there is a wide disparity in care for patients with multivisceral involvement from primary locally advanced and recurrent rectal cancer. The referral process and access to high-quality care has been inconsistent, and patients may be denied potentially curative surgery or experience delay in being considered for surgery, which can result in a poorer outcome. Data collection is variable as patients are not generally included in national databases and outcome reporting is dependent on audits and publications from individual centres.
The aim of the present study was to determine the impact of a multidisciplinary input in the selection process for and outcome of pelvic exenteration and to report the experience of a multidisciplinary team (MDT) dedicated to the treatment of advanced and recurrent colorectal cancer.
Method
Patients and the MDT Data from patients with locally advanced rectal cancer referred to the colorectal department of the Royal Marsden Hospital between January 2010 and December 2014 were included. They had undergone exenterative multivisceral surgery for locally advanced primary rectal cancer beyond TME (LAPRC b-TME), rectal recurrence (RR), locally advanced primary colon cancer (LAPCC), colon recurrence (CR), locally advanced primary anal cancer (LAPAC) and anal recurrence (AR) (see Definitions). All patients were discussed and assessed by the MDT, which included medical oncologists, colorectal surgeons, radiotherapists, radiologists, histopathologists, oncology and surgical specialist nurses. Plastic surgeons, urologists, gynaecologists and vascular surgeons were consulted when necessary but were not regular members of the MDT. Meetings were held weekly and the minutes were recorded by a MDT coordinator.
End-points
The primary end-point was the indications and outcome of the total number of patients referred for consideration of exenterative procedures. Those assessed and not operated on were determined and the total number of operations performed was identified. The main secondary end-points were resection margin status, length of stay (LOS), perioperative adverse events (ClavienDindo [15] complications 1-4), 30-day morbidity, 30-day mortality, re-admissions and referral pathway. Histopathological examination of the resected specimen was routinely performed to confirm the diagnosis and determine the anatomical pathology, including the status of the resection margin.
Definitions
The following definitions were used: LAPRC b-TME: locally advanced primary rectal cancer. This included patients with locally advanced primary rectal cancer beyond TME. These patients were identified by MRI, which predicted the need for an extended surgical resection beyond the TME plane to achieve an R0 resection. 
Results
In all, 954 referrals were made between January 2010 and December 2014 from other UK hospitals (39.5%), hospitals within our network (28.9%), general practice (14.0%), general practice within our network (6.9%) and overseas ( There were 16 sacrectomies, 134 total pelvic exenterations and 121 other multivisceral procedures (Table 2 ). An R0 resection was achieved in 94.4% of all cases, with R1 and R2 resections accounting for 5.1% and 0.3%. In 2010 the R0 resection rate was 93.9%, in 2011 it was 94.8%, in 2012 94.8%, in 2013 89.2% and in 2014 98.4%. The rate of R0 resection among LAPRC and RR was 93% with R1 and R2 resection comprising 6.4% and 0.5%, respectively. The R0 resection rate for LAPCC and CC was 98.6% with R1 and R2 being 1.4% and zero, respectively. In the case of LAPAC and AR the R0, R1 and R2 rates were 90%, 10% and zero, respectively ( Table 1 (Table 3) . There was no 30-or 90-day mortality.
Discussion
The goal of surgery for locally advanced rectal cancer is to achieve complete resection with clear histopathological margins [16, 17] . Pelvic multivisceral exenterative procedures were initially described by Brunschwig in 1948 for palliation of advanced cervical cancer [18] . These procedures have evolved to for radical resection of pelvic malignant disease, and when performed as a total pelvic exenteration (TPE) the procedure involves the en bloc resection of the pelvic tumour along with any invaded viscera including the rectum, distal colon, bladder, reproductive organs, lymph nodes and pelvic peritoneum. In some cases, the resection of muscles, ligaments and parts of the pelvic bone may be necessary and the dissection can involve the pelvic sidewall muscles, blood vessels and lymph nodes. Such major surgery has resulted in a high rate of postoperative complications and positive resection margins with varying survival rates and long-term functional disability [12] [13] [14] . Over time, improved patient selection and advances in imaging, surgical technique, perioperative care and MDT cooperation have led to reduced surgical mortality and morbidity [19, 20] .
Studies have shown that MDT input in complex diseases results in greater patient satisfaction [21] , changes in management [22] [23] [24] , improved staging [25, 26] , increased surgical experience [27] and increased survival [22, 23, [25] [26] [27] [28] [29] [30] . It is also well established that surgery by trained specialists, especially in rectal cancer, results in an improved outcome [31] [32] [33] [34] . The identification of patients eligible for surgery is a key element in optimizing the surgical results and survival [35] .
In the present series the rate of R0 resection, at 94.4%, was high. This had improved over time LAPRC and RR increased from 23 per year in 2010 to 46 per year in 2014. This was accompanied by more rigorous selection of patients for surgery despite the increased number of referrals and is ascribable to the effect of the formal MDT approach. In contrast, some centres treating locally advanced rectal cancer and other pelvic malignancies may apply different patient selection criteria for pelvic exenteration according to the experience and preference of the clinicians [36] . The indications to proceed with pelvic exenterative surgery for advanced rectal cancer include confinement of the malignant process to the pelvis and the absence of unresectable metastatic disease. Preoperative evaluation with MRI and CT with positron emission tomography (PET/CT) allows the assessment and characterization of patients with inoperable metastases who will therefore usually not be offered exenterative surgery [37, 38] .
Contraindications to pelvic exenterative surgery include anatomical, surgical, medical and psychological factors. There is a high degree of variability between treatment centres regarding relative contradictions such as the presence of distant metastases, metastases to para-aortic and/or supra-diaphragmatic lymph nodes, tumour fixation in multiple sites in the pelvis, unpredictable resection margins and tumour involving the sacrum at level S1-S2 [39, 40] . There appears to be general agreement on the absolute contraindications not to proceed with surgery, including inoperable metastatic disease, tumour involving bone above S1, unfitness for surgery and the patient's decision not to go ahead. Some centres do not have definite contraindications based on local involvement of the tumour, but MRI demonstrating that an R0 resection is possible technically is a reliable guide to the success of exenterative surgery [41] . Until recently there had been no standardization of definitions, with the consequence that accurate comparison of results between different units was not possible. An attempt has been has been made to address this with the publication in 2013 of the 'Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision (TME) planes' [42] . Three years later, however, it is still not clear how the service is currently being provided in the UK. There are still significant delays in the referral of patients and widespread geographical variation in the quality of service delivered. A proposed surgical algorithm for the management of extensive primary and recurrent rectal cancer is suggested in Figs 3 and 4 . It is expected that standardization of referral criteria, improved access to services, better coordination of care and careful assessment of individual patients through a dedicated complex colorectal cancer MDT should result in significant benefits to patients requiring pelvic exenteration. The treatment of locally advanced and recurrent rectal cancer is costly at all stages of the management pathway and further research is required to assess the cost-effectiveness of the service. It is, however, important to recognize that surgical resection is the only modality which can offer a cure, and in most cases patients are very keen to have surgery even if very extensive. Streamlined, standardized and well-communicated management should be able to deliver timely, cost-effective and high-quality care. A structured selection process can improve the outcome of surgery through a standardized approach to service delivery.
